Connect
← Return to Vitamin K: High Doses of MK-4 and MK-7 Show Promising Results
Discussion
Vitamin K: High Doses of MK-4 and MK-7 Show Promising Results
Osteoporosis & Bone Health | Last Active: Jun 6 10:56pm | Replies (107)Comment receiving replies
@daisy17 I also have some misgivings about the FDA changes, but the goal is to make the medications less expensive to trial and thus maybe more option and less expensive for us. I have been a tiny bit involved in medical research and doubt that the individual drugs as profitable as they seem on the surface. It is amazingly expensive to develop and trial a drug. Most drugs fail to get approved, and the successful ones have to cover the costs of all of the failures.
EXAMPLE: The history of strontium ranelate for osteoporosis is a sad chapter on many fronts. The drug company could not do the expensive trials on better-known strontium citrate SrC because there is no way for them to get their money back. Not-for-profit entities do not have enough funds to do full RCT out to fracture risk. I doubt that the change in the FDA policy will be sufficient for SrC research to be publicly funded, but it is a step in that direction. Note: I do not take strontium because of insufficient research. But it might work and I wish someone could do more research.
Replies to "@daisy17 I also have some misgivings about the FDA changes, but the goal is to make..."
Connect
@kfhoz If new bone drugs are approved, it will be interesting to see if the drug companies pass any savings resulting from less expensive trials on to the customers.
I found this info on some of the current bone drug companies:
Amgen's profits from Evenity have shown significant growth, with sales increasing 39% year-over-year to $599 million in the fourth quarter of 2025 and a total annual increase of 34% for the full year. In the first quarter of 2026, Evenity sales rose by 27% to $562 million, maintaining a strong market presence.
In 2021, Radius Health reported net revenue of $219 million from sales of Tymlos, which was an increase from $208 million in 2020. The company aims for Tymlos net revenue of $232 million in 2022.
Eli Lilly, the company that sells Forteo, reported $69.90 million in net sales for Forteo in a recent quarter, which represents a year-over-year change of -52.8%. This decline indicates a significant drop in sales compared to previous periods.
Amgen, the company that sells Prolia, reported an overall revenue increase of 6% for the first quarter of 2026, totaling $8.6 billion. However, Prolia's sales specifically were down 34% to $727 million during the same period due to biosimilar competition.